On 30 April 2024, the Food Standards Agency (FSA) and Food Standards Scotland (FSS) concluded based on the opinion of the Advisory Committee on Novel Foods and Processes (ACNFP) that novel foods, synthetic cannabidiol (CBD) and CBD isolate developed by Chanelle McCoy Ltd and Cannaray Ltd respectively were safe under the proposed conditions of use.
The cannabidiol, CBD, an active substance most often of natural origin, is one of the phyto-cannabinoids. CBD, as the tétrahydrocannabinol (THC ), is present in the cannabis flowers and leaves. It is a non-addictive psychotropic drug, unlike THC. It is also a component in the form of an extract, medicine, or everyday consumer products, only some of which are authorised in France under specific conditions of THC content. In addition, CBD is considered at European level as a novel food whose safety is currently being assessed by EFSA.
Following an exploration of potential regulatory pathways for cannabidiol (CBD) products by an internal Food and Drug Administration (FDA) working group, the FDA concluded on January 26, 2023, that a new regulatory pathway for CBD is needed to provide the regulatory oversight necessary to manage risk. The Agency is prepared to work with Congress on this issue.
On 28 June 2022, a webinar information session was held to present the recently published EFSA “Statement on safety of cannabidiol as a novel food: data gaps and uncertainties” to stakeholders.
Français